Lipid-Lowering Drug Therapy: Critical Approach for Implementation in Clinical PracticeIncreased levels of low-density lipoprotein cholesterol (LDL-C) are recognized as a primary risk factor for atherosclerotic cardiovascular disease, which remains the leading cause of death worldwide. Lowering LDL-C ...
Explain the indications for using the various agents in the lipid-lowering therapy family of medications. Review the adverse effect profile of various individuals lipid-lowering therapy agents. Describe interprofessional team strategies for improving care coordination and communication to properly use lipid-...
Lipid-lowering drugsStatinsGuidelinesPatients with type 2 and advanced type 1 diabetes bear a very high risk for cardiovascular disease, which is substantially driven by the associated dyslipidemia; therefore, patients with diabetes clearly benefit from intensive lipid-lowering therapy. To ensure optimal ...
lowering drug treatment for diabetic and non-diabetic patients: metaanalysis of randomised controlled trials. BMJ 2006; 332:1115-8. 2. Gupta A, Gupta V, Thapar S, Bhansali A. Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular oedema. Am J Ophthalmol. 2004 ...
Drug Therapy, CombinationCholesterol, LDLCholesterol, HDLClinical Trials as TopicHypolipidemic AgentsFibric AcidsLittle is known about the needs of older home care clients with dementia or their key quality of care issues, including their use of pharmacotherapy for Alzheimer's disease. The objectives ...
Drug therapy should be strongly considered in those patients with concentrations of atherogenic lipoproteins which exceed the 90th to 95th percentile for age. In patients with increased plasma concentrations of low density lipoproteins (LDL), agents which enhance the rate of LDL catabolism (...
This study was performed to quantify adherence rates to lipid-lowering drug therapy among members of the Canadian Forces (CF) and to identify factors associated with nonadherence.Pharmacy claims were reviewed for all CF members who received a lipid-lowering drug between April 1 and June 1, 2003....
摘要: OBJECTIVE: To review the effects of lipid-lowering therapy on small-dense low-density lipoprotein cholesterol (sdLDL-C). DATA SOURCES: Literature was obtained from MEDLINE (1989-Se... 查看全部>>关键词: Carbon ion Lipids Low density lipoprotein cholesterol measurement physical density 脂类 ...
Monitoring of Lipids, Enzymes, and Creatine Kinase in Patients on Lipid-Lowering Drug Therapy A number of plasma lipid parameters have been used to estimate cardiovascular risk and to be targets for treatment to reduce risk. Most risk algorithms are... O Wiklund,C Pirazzi,S Romeo - 《Current...
Leqvio (inclisiran), a cholesterol management drug that requires only two subcutaneous injections per year, is preparing to land in Korea.The Ministry of Food and Drug Safety (MFDS) is reportedly reviewing Novartis Korea's application to license Leqvio.